Maximum quantity allowed is 999
CAS RN: 82159-09-9 | Product Number: E0906
Epalrestat
Purity: >98.0%(T)(HPLC)
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 1G |
$49.00
|
2 | 14 | Contact Us | |
| 5G |
$155.00
|
1 | 19 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | E0906 |
Purity / Analysis Method
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__5H__1__3NO__3S__2 = 319.39 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 82159-09-9 |
| Reaxys Registry Number | 4236712 |
| PubChem Substance ID | 172089065 |
| Merck Index (14) | 3605 |
| MDL Number | MFCD00865484 |
| Appearance | Light yellow to Amber to Dark green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 222.0 to 226.0 °C |
| NMR | confirm to structure |
| Melting Point | 224 °C |
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H300 : Fatal if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
| RTECS# | XJ5131855 |
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | II |
| H.S.code* | 2934.10-000 |
References
- Effects of a new aldose reductase inhibitor on various tissues in vitro
- H Terashima, K Hama, R Yamamoto, M Tsuboshima, R Kikkawa, I Hatanaka, Y Shigeta, J. Pharmacol. Exp. Ther. 1984, 229, 226.
- Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients
- An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-β and protein kinase C activity in cultured human mesangial cells
- Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase
- Aldose reductase structures: Implications for mechanism and inhibition
- Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy
- M. A. Ramirez, N. L. Borja, Pharmacotherapy 2008, 28, 646.
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.